文献速递胸部肿瘤

中国肺癌患者EGFR与ERBB2胚系突变及其在癌症遗传易感性中的作用

EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer.
PubMed 文献 · J Thorac Oncol · 2019-01-02

该研究回顾性分析12,833例中国肺癌患者的靶向二代测序数据,检出14例腺癌患者携带8种不同EGFR胚系突变(0.12%),仅1例携带ERBB2-V1128I胚系突变。15例中5例有癌症家族史,EGFR-T790M胚系突变患者有多名母系家族成员患肺癌。无其他已知驱动突变的患者可能从酪氨酸激酶抑制剂治疗中获益。

要点

  • 中国肺癌患者中EGFR/ERBB2胚系突变罕见,EGFR-K757R为最常见的EGFR胚系突变。
  • EGFR-T790M胚系突变患者有多名母系家族成员患肺癌,支持其在遗传性肺癌中的作用。
  • 无其他已知驱动突变的EGFR胚系突变患者可能从酪氨酸激酶抑制剂治疗中获益。

核心结论

  • EGFR/ERBB2胚系突变在中国肺癌患者中罕见,且多样性高于既往报道的EGFR-T790M,其中EGFR-K757R为最常见的EGFR胚系突变。
  • 无其他已知驱动突变的EGFR胚系突变患者可能从酪氨酸激酶抑制剂治疗中获益。

研究设计与样本

  • 回顾性分析12,833例接受靶向二代测序的中国肺癌患者队列,鉴定携带EGFR和ERBB2胚系突变的患者并总结其临床信息与家族史。
  • 对EGFR胚系突变的生长因子非依赖性进行体外分析。

主要发现

  • 从14例腺癌患者(0.12%)中鉴定出8种不同的杂合EGFR胚系突变,位于激酶结构域内或邻近区域,包括K757R(n=5)、R831H(n=2)、D1014N(n=2)、G724S、V786M、T790M、L792F和L844V。
  • 仅1例患者携带ERBB2-V1128I胚系突变。
  • 15例患者中5例有癌症家族史;EGFR-T790M胚系突变患者有多名母系家族成员被诊断为肺癌。
  • 5例患者在诊断时未检测到并发的已知体细胞驱动突变,其中1例携带EGFR-L844V胚系突变并对阿法替尼表现出优异缓解。
  • 体外实验中EGFR-K757R和L844V突变能够不依赖白细胞介素3,并对EGFR酪氨酸激酶抑制剂敏感。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Inherited genetic determinants of lung cancer risk remain relatively elusive. Germline mutations in EGFR and erb-b2 receptor tyrosine kinase 2 (ERBB2) have been previously reported in lung cancers that may be associated with genetic susceptibility to lung cancer. METHODS: We retrospectively analyzed a cohort of 12,833 Chinese lung cancer patients tested by targeted next-generation sequencing. Patients with EGFR and ERBB2 germline mutations were identified, and their clinical information and family history were summarized. Growth factor independency of EGFR germline mutations was further analyzed in vitro. RESULTS: Eight different heterozygous EGFR germline mutations from 14 adenocarcinoma patients (0.12%) were identified within or adjacent to the kinase domain, including K757R (n = 5), R831H (n = 2), D1014N (n = 2), G724S, V786M, T790M, L792F, and L844V. Only one patient harbored the ERBB2-V1128I germline mutation. Five of 15 patients had family history of cancer. Notably, the patient with EGFR-T790M germline mutation had multiple maternal family members diagnosed with lung cancers, strongly supporting its role in inherited lung cancer. Concurrent known somatic driver mutations were not detected in 5 patients at diagnosis, 1 of whom harbored the EGFR-L844V germline mutation and showed superior response to afatinib. Consistently, EGFR-K757R and L844V mutations were able to be interleukin 3 - independent in vitro and were sensitive to EGFR tyrosine kinase inhibitors. CONCLUSIONS: EGFR/ERBB2 germline mutations were found to be rare in Chinese lung cancer patients with more diversity other than the previously reported EGFR-T790M, with EGFR-K757R being the most common EGFR germline mutation. Patients with EGFR germline mutations without other known driver mutations might benefit from tyrosine kinase inhibitor treatment.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Lu S, Yu Y, Li Z, et al. EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer. J Thorac Oncol. 2019. PMID: 30610926. doi:10.1016/j.jtho.2018.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。